A carregar...
Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition
The AURELIA trial demonstrated that adding Bevacizumab to chemotherapy significantly improved progression-free survival (PFS) for platinum resistant recurrent ovarian cancer. Recently, immunotherapy also presented potential anti-tumor effects in several malignant solid tumors. This study aimed to in...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6498972/ https://ncbi.nlm.nih.gov/pubmed/31105696 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.00867 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|